drugset / Trial / NCT03330418
A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to initially observe the safety and effectivity of RC18 in Participants with Neuromyelitis Optica Spectrum Disorders.
Timeline
- Start
- 2018-01-29
- Primary completion
- 2026-04-03
- Completion
- 2026-04-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Telitacicept | Protein / enzyme biologic | 160 mg | Subcutaneous |